Lyell Immunopharma, Inc. (LYEL) — Revenue
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $36.0K | -41.0% |
| 2024 | $61.0K | -53.1% |
| 2023 | $130.0K | -99.8% |
| 2022 | $84.68M | +695.1% |
| 2021 | $10.65M | +37.3% |
| 2020 | $7.76M | +1080.5% |
| 2019 | $657.0K | — |
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $36.0K | -41.0% |
| 2024 | $61.0K | -53.1% |
| 2023 | $130.0K | -99.8% |
| 2022 | $84.68M | +695.1% |
| 2021 | $10.65M | +37.3% |
| 2020 | $7.76M | +1080.5% |
| 2019 | $657.0K | — |